Figure 2 | Scientific Reports

Figure 2

From: Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease

Figure 2

Differences in sFRP5 and Wnt5a levels between patients from ICU cohort with severe Covid-19 infection (cases) and healthy controls from FoCus cohort. (A) Subjects with Covid-19 disease showed significant lower sFRP5 levels compared to healthy controls. (B) Levels of Wnt5a were significantly increased in cases compared to healthy controls. Wilcoxon Test; statistical significance p < 0.05.

Back to article page